Go Back Menu
Close
Products
No.1 in prescriptions and still
growing faster
Mankind's prescription portfolio cover both acute and chronic therapeutic areas
The diversified portfolio puts a de-risked strategy in place across booming segments. There has been a conscious move to focus on the chronic segment in the recent past, with the share rising to 36% (FY24) compared to 18% (FY18). Our growth in prescriptions has consistently outpaced the Indian pharma market growth rate.
#1
in prescriptions over
7 years
7 years
#2
in covered market in
FY23
FY23
#3
Rank by
volume
volume
#4
Rank by
value
value
Our Products
Our portfolio of 500+ products comprises a broad range of formulations across various acute and chronic therapeutic areas.
Anti-infectives
15%
Anti-infectives portfolio share in domestic sales
cardiovascular
15%
Cardiovascular portfolio share in domestic sales
Gastrointestinal
10%
Gastrointestinal portfolio share in domestic sales
Respiratory
9%
Respiratory portfolio share in domestic sales
Vitamins / Minerals / Nutrients
8%
VMN portfolio share in domestic sales
Anti-Diabetic
9%
Anti-diabetic portfolio share in domestic sales
Gynaecology
8%
Gynaecology portfolio share in our domestic sales
Dermatology
5%
Dermatology portfolio share in domestic sales
Pain / Analgesics
4%
Pain / Analgesics portfolio share in domestic sales
Neuro / CNS
3%
Neuro/CNS portfolio share in domestic sales
